Harnessing the innate immune system to treat inflammation, autoimmune disease
and cancer

About Us

ImmuneSensor Therapeutics is a clinical-stage biotechnology company focused on developing novel medicines that target the cGAS-STING pathway to modulate the innate immune system. Based on groundbreaking discoveries from the research of the 2019 Breakthrough Prize awardee, Dr. Zhijian James Chen, we are pioneering a differentiated approach with best-in-class cGAS inhibitors to suppress inflammation and autoimmunity when the immune system is overactive and STING activators to initiate and enhance anticancer immunity.

Learn More

cGAS-STING Pathway

Immunesensor

Discovery of cGAS – the cytoplasmic DNA-sensing enzyme ‐ and its secondary messenger cGAMP ‐ by Dr. Chen's laboratory in 2012 has revolutionized research and drug development efforts into the role of the cGAS-STING pathway in innate immunity and disease. The broad applicability of the pathway in diverse therapeutic areas is now widely recognized to play a critical role in activating innate immune defense triggered by cytosolic DNA from pathogens, cellular stress and damaged tumor cells.

At ImmuneSensor we are leveraging this critical central pathway in the progression of diverse diseases to develop best-in-class cGAS inhibitors for the treatment of a range of inflammatory and autoimmune diseases along with immune stimulatory STING agonists, formulated as small molecules or as antibody drug conjugates (ADC), for the treatment of cancers.

Learn More

Our Pipeline

We are advancing differentiated potentially first- and
best-in-class candidates with the goal of improving the lives of
patients with serious and rare disease.

couple hiking in the woods

IMSA101

STING
Agonist

Designed to activate STING to turn "cold" tumors "hot"
cells background

IMSA201

2nd Generation
STING Agonist

Focused on targeted delivery of STING agonist using an ADC
DNA strand

cGAS
Antagonists

Aimed at dampening an abnormal immune response by inhibiting cGAS

Learn More